Company intelligence / Profile preview

Kangqing Biotech

Hangzhou, Zhejiang Sheng, Chinaeosinc999.us ↗

Ownership: Private
Development stage: Other

Overview

KL003, the lead asset targeting beta thalassemia and sickle cell disease, has shown encouraging efficacy signals and a favorable safety profile in Phase 1 studies. Manufacturing costs are reportedly lower than currently approved gene therapies. A pivotal Phase 2 study is expected to start in 2025. Other pipeline programs are at earlier stages targeting hemophilia, Parkinson’s disease, and HIV/AIDS.

Therapeutic areas: Infectious DiseasesNeurologyHematology
Modalities: Gene therapyAAV based gene therapyHematopoietic stem cell therapy
Industry: Biotech

Partnerships

No major pharmaceutical or biotech partnerships publicly disclosed as of June 2025.

Beyond the preview

Go deeper on Kangqing Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kangqing Biotech.

Explore the full profile